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Aims Sudden cardiac death (SCD) is a major contributor to the excess mortality of patients on maintenance dialysis.
Homoarginine deﬁciency may lead to decreased nitric oxide availability and endothelial dysfunction. Based on this
rationale we assessed whether homoarginine deﬁciency is a risk factor for SCD in dialysis patients.
Methods and
results
This study examined the association of homoarginine with cardiovascular outcomes in 1255 diabetic haemodialysis
patients from the German diabetes and dialysis study. During a median of 4 years of follow-up, hazard ratios (HR)
(95% CI) for reaching the following pre-speciﬁed, adjudicated endpoints were determined: SCD, myocardial infarc-
tion, stroke, death due to heart failure, and combined cardiovascular events. There was a strong association of low
homoarginine concentrations with the presence of congestive heart failure and left ventricular hypertrophy as well as
increased levels of brain natriuretic peptide. Per unit decrease in homoarginine, the risk of SCD increased three-fold
(HR 3.1, 95% CI 2.0–4.9), attenuating slightly in multivariate models (HR 2.4; 95% CI 1.5–3.9). Patients in the lowest
homoarginine quintile experienced a more than two-fold increased risk of SCD, and more than three-fold increased
risk of heart failure death than patients in the highest quintile, which accounted for the high incidence of combined
cardiovascular events. Low homoarginine showed a trend towards increased risk of stroke, however, myocardial
infarction was not meaningfully affected.
Conclusion Low homoarginine is a strong risk factor for SCD and death due to heart failure in haemodialysis patients. Further
studies are needed to elucidate the underlying mechanisms, offering the potential to develop new interventional
strategies.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Despite efforts to improve outcomes in renal replacement therapy,
mortality of patients undergoing haemodialysis remains unaccepta-
bly high.
1–3 Cardiac and vascular events are the predominant
causes of death.
1 The major cause of death is sudden cardiac
death (SCD); accounting for one quarter of all deaths in dialysis
patients.
1,2,4 Understanding the mechanisms of SCD and identifying
risk factors are essential for developing novel interventional strat-
egies and to reduce the excess mortality of dialysis patients.
Homoarginine is a cationic amino acid, which is derived from
lysine and mainly synthesized in the kidney by transamination of
its precursor.
5,6 Evidence suggests that homoarginine increases the
availability of nitric oxide (NO),
7–12 a lack of which is associated
with endothelial and myocardial dysfunction.
9–12 Studies have
shown that homoarginine serves as a precursor of NO by increasing
* Corresponding author. Tel: +49 931 201 39030, Fax: +49 931 201 639300, Email: c.drechsler@gmx.net
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2011. For permissions please email: journals.permissions@oup.com.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions@oup.com
European Journal of Heart Failure (2011) 13, 852–859
doi:10.1093/eurjhf/hfr056the intracellular concentration of L-arginine, which is the main sub-
strate for NO synthase.
9–12 Importantly, a recent study documen-
ted that low blood concentrations of homoarginine are associated
with markedly increased mortality in patients referred for coronary
angiography and in patients undergoing haemodialysis.
13 In addition,
homoarginine was inversely correlated to markers of impaired
endothelial function, i.e. to the intercellular adhesion molecule 1
(ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1). Further-
more, homoarginine was associated with the prevalence of heart
failure, incrementally increasing at lower levels of homoarginine.
13
We reasoned that endothelial dysfunction may play a crucial role
in the arrhythmogenesis of patients with kidney failure and tested
the hypothesis that low blood concentrations of homoarginine
increase the risk of SCD in dialysis patients. We analysed data
from the German diabetes dialysis study (4D Study: Die Deutsche
Diabetes Dialyse Studie), which was a prospective study evaluating
atorvastatin in 1255 patients with type 2 diabetes mellitus under-
going maintenance haemodialysis.
4
Methods
Study design and participants
The methodology of the 4D study has previously been reported in
detail.
14 Brieﬂy, the 4D study was a prospective randomized controlled
trial of 1255 patients with type 2 diabetes mellitus, aged 18–80 years,
who started haemodialysis within the last 2 years. Between March
1998 and October 2002, patients were recruited from 178 dialysis
centres in Germany. After a run-in period of 4 weeks, patients were
randomly assigned to double-blinded treatment with either 20 mg
atorvastatin (n ¼ 619) or placebo (n ¼ 636) once daily. Study visits
took place three times before randomization (Visit 1–3), at randomiz-
ation (Visit 4), at 4 weeks (Visit 5), and then every 6 months (Visit 6,
etc.) after randomization until the date of death, censoring, or the end
of the study in March 2004. At each follow-up, blood samples were
taken and clinical information including any adverse events, and an
electrocardiogram was recorded. The study conformed to the prin-
ciples outlined in the Declaration of Helsinki. It was approved by the
appropriate medical ethics committee, and all patients gave their
written informed consent before inclusion.
Data collection
Information on age, gender, and smoking status was obtained through
patient interviews. Smoking status was classiﬁed as never, former, or
current. Comorbidities, including the presence of coronary artery
disease (CAD) and congestive heart failure (CHF), as well as the dur-
ation of diabetes mellitus, and dialysis treatment were reported by the
patients’ nephrologists. Coronary artery disease was deﬁned as a
history of myocardial infarction (MI), coronary artery bypass grafting
surgery; percutaneous coronary intervention; and the presence of cor-
onary heart disease, as documented by coronary angiography. Blood
pressure was measured in sitting position. Body mass index (BMI)
was calculated as weight (kg) divided by height (m) squared.
Homoarginine measurement
Homoarginine was measured in blood samples taken at baseline during
study Visit 3 (1 week before randomization)., using a reverse-phase
high-performance liquid chromatography method.
15,16 Samples were
stored at 2808C prior to analysis. Within-day coefﬁcients of variation
(CV) were 4.7% (1.21 mM) and 2.2% (3.53 mM), and between-day CV
were 7.9% (1.25 mM) and 6.8% (3.66 mM), respectively. All blood
samples were taken before the start of dialysis sessions and adminis-
tration of drugs.
Outcome assessment
The primary endpoint of the 4D study was deﬁned as a composite of
death from cardiac causes, fatal or non-fatal stroke, and non-fatal MI,
which ever occurred ﬁrst (composite cardiovascular endpoint; CVE).
Death from cardiac causes comprised SCD, fatal MI, death due to con-
gestive heart failure, death due to coronary heart disease during or
within 28 days after an intervention, and all other deaths attributable
to coronary heart disease. Sudden cardiac death was considered as:
death as veriﬁed by terminal rhythm disorders in an electrocardiogram;
by witnesses observed death within 1 hour after the onset of cardiac
symptoms; conﬁrmed by autopsy; unexpected death, presumably or
possibly of cardiac origin and in the absence of a potassium level
≥7.5 mmol/L before the start of the three most recent sessions of
haemodialysis. Myocardial infarction was diagnosed when two of the
following three criteria were met: typical symptoms, elevated levels
of cardiac enzymes (i.e. creatine kinase MB above 5% of the total
level of creatine kinase, lactic dehydrogenase 1.5 times the upper
limit of normal, or a troponin T level .2 ng/mL), or diagnostic
changes on the electrocardiogram. When death occurred within 28
days after an MI as diagnosed above, it was speciﬁed as death due to
MI. The classiﬁcations were made exclusively, with fatal MI only
being classiﬁed as MI death, and not SCD. Stroke was deﬁned as a
neurological deﬁcit lasting longer than 24 hours. Computed tomo-
graphic or magnetic resonance imaging was available in all but 16 cases.
The 4D study endpoints were centrally adjudicated by three
members of the endpoint committee blinded to study treatment and
according to pre-deﬁned criteria.
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For the present analysis, SCD, MI (fatal and non-fatal), stroke (fatal
and non-fatal), death due to CHF, and the primary endpoint of com-
bined CVE, were all chosen as separate outcome measures. The categ-
orization of these events was based on the primary judgement of the
endpoint committee during the 4D study.
Statistical analysis
Continuous variables are expressed as mean with standard deviation
or median with interquartile range (IQR) as appropriate, and categori-
cal variables are expressed as percentages.
The study population was divided into ﬁve groups, according to
quintiles of homoarginine levels at baseline: ≤0.81 mmol/L, .0.81 to
≤1.0 mmol/L, .1.0 to ≤ 1.2 mmol/L, .1.2 to ≤1.48 mmol/L,
.1.48 mmol/L. First, we assessed the association of baseline homoar-
ginine with SCD both as a continuous and as a categorical variable. For
the latter, the patients in the highest homoarginine quintile were used
as the reference group. Absolute (incidence) rates were calculated, and
relative risks derived from Cox regression analyses, i.e. hazard ratios
(HRs) and corresponding 95% conﬁdence intervals. The Cox
regression analyses were adjusted for the confounders: age, sex, ator-
vastatin treatment, duration of dialysis, CAD, smoking status, BMI, low-
density lipoprotein-cholesterol, haemoglobin, and albumin. Second, to
explore potential pathways, we performed additional analyses with
inclusion of potential intermediate conditions as suggested from pre-
vious experimental and clinical research: we additionally adjusted our
analyses for congestive heart failure, arrhythmia as deﬁned by the
absence of sinus rhythm, levels of brain natriuretic peptide, C-reactive
protein, blood pressure, HbA1c, and calcium and phosphate as
markers of mineral metabolism. Third, we investigated homoarginine
and the risk of other adverse cardiac and vascular outcomes including
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point, to distinguish whether the potential effects of homoarginine are
speciﬁc for SCD, or generally inﬂuence cardiac and vascular outcomes.
Finally, to exclude potential interaction by atorvastatin treatment, we
repeated our analyses stratiﬁed by medication.
All P values are reported as two sided. Analyses were performed
using SPSS version 16.0.
Results
Patient characteristics
Of the 1255 patients included in the 4D study, 1244 patients had a
homoarginine measurement at baseline. The mean follow-up period
was 3.96 years (median 4.0 years) on atorvastatin and 3.91 years
(median 4.08 years) on placebo. During follow-up, 617 patients
died, including 160 patients who died of SCD, and 41 patients who
died due to congestive heart failure. A total of 469 patients reached
the primary endpoint of CVE with MI (fatal or non-fatal), and stroke
(fatal or non-fatal) occurring in 200 and 103 patients, respectively.
The mean (standard deviation) homoarginine concentration at
baseline was 1.2 (0.5) mmol/L; with no signiﬁcant difference
between the atorvastatin and placebo groups. The baseline patient
characteristics are shown in Table 1. Homoarginine concentrations
were lower at higher age, lower BMI, lower albumin, lower haemo-
globin, and were lower in females as compared to males. Low
homoarginine concentrations were furthermore associated with a
longer history of diabetes mellitus and higher levels of C-reactive
protein. Most importantly, there was a strong consistent relation
of low homoarginine concentrations with indicators of impaired
cardiac function, including an increased prevalence of CHF and
left ventricular hypertrophy as well as incrementally increasing
levels of brain natriuretic peptide at lower levels of homoarginine.
Homoarginine and the risk of sudden
cardiac death
Lower homoarginine levels at baseline were associated with higher
incidences of SCD. Per unit decrease in homoarginine (continuous
variable), the crude risk of SCD signiﬁcantly increased more than
.........................................................................................................................................
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Table 1 Patient characteristics according to quintiles of homoarginine concentration at baseline; study population n 5
1244
Characteristic Homoarginine concentration at baseline (mmol/L)
Quintile 1 ≤0.81
(n5258)
Quintile 2 >0.81 to
≤1.0 (n5246)
Quintile 3 >1.0 to
≤1.2 (n5257)
Quintile 4 >1.2 to
≤1.48 (n5239)
Quintile 5 >1.48
(n5244)
Age (years) 68 (7) 65 (9) 66 (8) 65 (8) 64 (8)
Gender (%) male 32 48 58 59 74
BMI (kg/m
2) 26.5 (4.7) 27.1 (4.9) 27.7 (5.1) 28.0 (4.6) 28.5 (4.5)
Atorvastatin treatment (%) 48 46 48 49 55
Arterial hypertension (%) 89 89 86 89 91
Systolic BP (mmHg) 144 (23) 146 (24) 147 (21) 145 (21) 146 (21)
Diastolic BP (mmHg) 74 (11) 76 (13) 75 (11) 76 (10) 77 (10)
Smoker/ex-smoker (%) 31 40 41 45 46
Duration of diabetes (years) 19.1 (9.1) 18.6 (8.2) 18.2 (8.5) 17.8 (9.0) 16.7 (8.9)
Time on dialysis (months) 9.2 (7.2) 8.0 (6.3) 7.9 (6.5) 8.4 (6.8) 7.6 (7.3)
History of
CAD (%) 28 36 27 27 29
CHF (%) 44 37 35 29 32
Absence of sinus rhythm (%) 15 17 11 13 7
Laboratory parameters
Total cholesterol (mg/dL) 223 (46) 217 (44) 221 (43) 217 (40) 217 (40)
LDL cholesterol (mg/dL) 130 (34) 126 (28) 127 (30) 121 (29) 124 (28)
HDL cholesterol (mg/dL) 37 (13) 36 (13) 37 (14) 36 (13) 35 (12)
Albumin g/dL 3.7 (0.3) 3.8 (0.3) 3.8 (0.3) 3.9 (0.3) 3.9 (0.3)
Haemoglobin g/dL 10.7 (1.5) 10.9 (1.3) 11.0 (1.3) 11.0 (1.4) 11.1 (1.3)
Calcium mmol/L 2.3 (0.2) 2.3 (0.3) 2.3 (0.2) 2.3 (0.2) 2.3 (0.2)
Phosphate (mmol/L) 6.2 (1.9) 6.0 (1.7) 6.0 (1.6) 6.1 (1.5) 5.8 (1.4)
NT-proBNP (pg/mL) 6221 (2426–
15728)
4600 (2064–10608) 3045 (1513–6832) 2456 (1054–6400) 2045 (896–5079)
C-reactive protein (mg/L) 5.8 (2.5–16.8) 4.9 (2.2–13.3) 4.6 (2.1–12.3) 5.1 (2.2–12.3) 4.9 (2.3–10.7)
Values are presented as means (SD) or median (interquartile range), or%.
BMI, body mass index; BP, blood pressure; HbA1c, glycated haemoglobin A1c; CAD, coronary artery disease; CHF, congestive heart failure; LDL, low-density lipoprotein; HDL,
high-density lipoprotein.
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persisted after adjustment for confounders (HR 2.4, 95% CI 1.5–
3.9). When patients were divided into quintiles according to
their homoarginine level at baseline, the risk increased incremen-
tally: patients in the lowest homoarginine quintile exhibited a
.2-fold higher risk of SCD (HR adjusted 2.1 95% CI: 1.2–3.9),
as compared to those in the highest quintile (Table 3 and Figure 1A).
We investigated potential intermediate pathways and addition-
ally adjusted our analyses for congestive heart failure, arrhythmia,
brain natriuretic peptide levels, C-reactive protein, blood pressure,
HbA1c, and markers of mineral metabolism. As expected, the
effect estimates decreased, supporting the existence of the
suggested mechanisms of homoarginine action.
Homoarginine and the risk of myocardial
infarction, stroke, death due to heart
failure, and combined cardiovascular
events
In contrast to the results seen for SCD, homoarginine did not
meaningfully affect the risk of MI. Both in continuous (HR adjusted
1.0, 95% CI 0.7–1.3) and in categorical analyses, the incidence of
MI did not increase over varying concentrations of homoarginine
(Tables 2 and 3, Figure 1B). When non-fatal and fatal MIs were ana-
lysed separately, the results were similar showing no association
with homoarginine.
An increased risk of stroke was observed at low levels of homo-
arginine in unadjusted analyses. This association was partly attenu-
ated after adjustment for confounders, leaving a trend for low
homoarginine concentrations to increase the risk of stroke. Impor-
tantly, the adjusted analyses revealed a strong relation of low
homoarginine with the risk of death due to heart failure. Patients
with lowest levels in the ﬁrst homoarginine quintile were three
times more likely to die of heart failure than patients in the
highest homoarginine quintile.(Table 3).
When investigating cardiovascular events combined as reﬂected
by the primary endpoint of the 4D study, the incidence of the
latter was markedly higher at lower concentrations of homoargi-
nine (Figure 1C). Patients in the lowest homoarginine quintile had
an 80% increased risk of developing a cardiovascular event,
which remained increased by 50% after adjustment for confoun-
ders (Table 3). Based on our analyses investigating the single end-
points, we were interested to know whether this increased risk of
the combined primary endpoint was mainly explained by the effect
of homoarginine on sudden cardiac and heart failure deaths. When
excluding these, no association was seen for the primary endpoint
any longer (Tables 2 and 3).
In order to strengthen our results, and to eliminate any
potential inﬂuence of atorvastatin treatment, we repeated all
analyses in the placebo group only. The results were similar,
indicating no interaction and supporting the use of the complete
data.
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Table 2 Absolute rates of sudden cardiac death, myocardial infarction , stroke, primary endpoint, heart failure death,
sudden or heart failure death combined, and the primary endpoint except for sudden or heart failure death; and hazard
ratios (95% CI) per unit decrease in homoarginine; n 5 1244
Sudden cardiac death Myocardial infarction Stroke Heart failure death
Events 160 200 103 41
Person-years (py) 3555 3368 3465 3555
Incidence rate/100 py 4.5 5.9 3.0 1.2
HR (95% CI)
Homoarginine unadjusted 3.1 (2.0–4.9) 1.0 (0.8–1.4) 2.0 (1.1–3.0) 1.6 (0.8–3.5)
Homoarginine adjusted
a 2.4 (1.5–3.9) 1.0 (0.7–1.3) 1.3 (0.8–2.1) 1.9 (0.8–4.4)
Homoarginine adjusted
b 2.2 (1.4–3.5) 0.9 (0.6–1.2) 1.2 (0.7–1.9) 1.3 (0.5–2.9)
Primary endpoint
c Sudden or heart
failure death
Primary endpoint except for
sudden or heart failure death
Events 469 201 268
Person-years (py) 3287 3555 3287
Incidence rate/100 py 14.3 5.7 8.2
HR (95% CI)
Homoarginine unadjusted 1.6 (1.3–2.0) 2.7 (1.9–4.0) 0.9 (0.7–1.2)
Homoarginine adjusted
a 1.3 (1.1–1.7) 2.3 (1.5–3.5) 1.0 (0.8–1.4)
Homoarginine adjusted
b 1.2 (0.9–1.5) 2.0 (1.3–3.0) 1.1 (0.9–1.5)
aAdjusted hazard ratio: Adjustments were made for age, sex, atorvastatin treatment, time on dialysis, smoking status, body mass index, levels of LDL-cholesterol, albumin,
haemoglobin, and the presence of coronary artery disease (as deﬁned by history of myocardial infarction, coronary artery bypass grafting surgery, percutaneous coronary
intervention, coronary heart disease documented by coronary angiography).
bAdjusted hazard ratio: additional adjustments were made for potential intermediate conditions including congestive heart failure, arrhythmia as deﬁned by the absence of sinus
rhythm, levels of N-terminal-pro-B-type natriuretic peptide, C-reactive protein, HbA1c, calcium, phosphate, and systolic and diastolic blood pressure.
cThe primary endpoint was a composite of death from cardiac causes, fatal stroke, non-fatal myocardial infarction, or non-fatal stroke, whichever occurred ﬁrst.
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We analysed data from 1255 haemodialysis patients with type 2
diabetes mellitus, who took part in the 4D study and experienced
a high incidence of pre-speciﬁed and centrally adjudicated end-
points. In the present analysis, low baseline homoarginine concen-
tration was a strong risk factor for SCD and death due to heart
failure during 4 years of follow-up. In patients of the lowest homo-
arginine quintile, the risk of dying suddenly was more than twice as
high, and the risk of death due to heart failure three times as high
compared to those of the highest homoarginine quintile. Further-
more, there was a trend for low homoarginine concentrations to
increase the risk of stroke; however, MI was not affected. The inci-
dence of the combined primary endpoint was signiﬁcantly higher at
lower concentrations of homoarginine, and this was mainly
explained by the effect of homoarginine on sudden cardiac and
heart failure deaths.
In advanced chronic kidney disease and end-stage renal
disease, the pattern and composition of cardiovascular risk is
changing. It is determined by various components such as
SCD, stroke, and MI, and may vary with changing proportions
of these components. In the general population, cardiovascular
risk is mainly determined by the incidence of MI, representing
the most frequent cause of death. In contrast, dialysis patients
pre-dominantly die of SCD, which as a single cause accounts
for one quarter of all deaths.
1,2 Various causes may account
for SCD in dialysis patients, including microvascular and macro-
vascular disease, sympathetic over-activity, structural heart
disease, cardiac ﬁbrosis, and electrolyte and volume shifts due
to the haemodialysis procedure.
17,18 Furthermore, we have
recently shown that poor glycaemic control and vitamin D
deﬁciency were strongly associated with the incidence of SCD
in dialysis patients.
19,20 Despite these advances in the evaluation
of risk factors, current knowledge is still limited, i.e. the known
risk factors do not sufﬁciently explain the excess rate of SCD
in dialysis patients.
The present work is the ﬁrst study to identify low homoargi-
nine concentrations as a novel risk factor for SCD in dialysis
patients. Evidence suggests that homoarginine may increase NO
availability, the lack of which is associated with endothelial, and
myocardial dysfunction.
9–12 In a previous study, we found an
inverse association between homoarginine and markers of
impaired endothelial function (ICAM-1 and VCAM-1).
13 Further-
more, we found an association between indicators of inﬂam-
mation including albumin and CRP, and low homoarginine
concentration. Endothelial dysfunction and inﬂammation may
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Table 3 Hazard ratio and 95% conﬁdence interval of sudden cardiac death, myocardial infarction, stroke, death due to
heart failure, combined cardiovascular events, sudden and heart failure deaths combined, and cardiovascular events
except for sudden and heart failure deaths, by quintiles of homoarginine at baseline; study population n 5 1244
Outcome Homoarginine levels at baseline (mmol/L)
Quintile 1 ≤0.81
(n 5 258)
Quintile 2 > 0.81 to
≤1.0 (n 5 246)
Quintile 3 > 1.0 to
≤1.2 (n 5 257)
Quintile 4 > 1.2 to
≤1.48 (n 5 239)
Quintile 5 > 1.48
(n 5 244)
Sudden cardiac death
Crude HR (95% CI) 2.9 (1.7–5.1) 2.7 (1.6–4.8) 2.0 (1.1–3.6) 1.5 (0.8–2.7) 1
Adj.
a HR (95% CI) 2.1 (1.2–3.9) 2.2 (1.2–3.9) 1.9 (1.1–3.4) 1.4 (0.7–2.5) 1
Myocardial infarction
Crude HR (95% CI) 1.1 (0.7–1.8) 1.0 (0.7–1.6) 1.1 (0.8–1.7) 0.8 (0.5–1.3) 1
Adj.
a HR (95% CI) 1.1 (0.7–1.7) 1.0 (0.6–1.5) 1.1 (0.7–1.7) 0.8 (0.5–1.3) 1
Stroke
Crude HR (95% CI) 2.6 (1.4–4.9) 1.4 (0.7–2.9) 1.8 (0.9–3.5) 1.1 (0.5–2.3) 1
Adj.
a HR (95% CI) 1.7 (0.9–3.3) 1.2 (0.6–2.5) 1.6 (0.8–3.2) 1.0 (0.5–2.1) 1
Death due to heart failure
Crude HR (95% CI) 2.6 (0.9–7.4) 1.8 (0.6–5.4) 1.9 (0.6–5.7) 1.6 (0.5–4.9) 1
Adj.
a HR (95% CI) 3.3 (1.1–10.1) 1.9 (0.6–6.0) 1.9 (0.6–5.9) 1.7 (0.5–5.2) 1
Cardiovascular events
Crude HR (95% CI) 1.8 (1.4–2.4) 1.5 (1.1–2.1) 1.4 (1.1–1.9) 1.1 (0.8–1.5) 1
Adj.
a HR (95% CI) 1.5 (1.1–2.0) 1.4 (1.0–1.8) 1.4 (1.0–1.8) 1.0 (0.7–1.4) 1
Sudden or heart failure death
Crude HR (95% CI) 2.8 (1.7–4.7) 2.5 (1.5–4.2) 2.0 (1.2–3.3) 1.5 (0.9–2.6) 1
Adj.
a HR (95% CI) 2.3 (1.4–3.9) 2.2 (1.3–3.6) 1.9 (1.1–3.2) 1.4 (0.8–2.5) 1
Cardiovascular events except sudden or heart failure death
Crude HR (95% CI) 1.4 (0.9–2.0) 1.1 (0.7–1.6) 1.2 (0.8–1.7) 0.9 (0.6–1.3) 1
Adj.
a HR (95% CI) 1.1 (0.8–1.7) 1.0 (0.7–1.4) 1.1 (0.8–1.7) 0.8 (0.6–1.3) 1
aModel 1: age, sex, atorvastatin treatment, time on dialysis, smoking status, body mass index, levels of LDL-cholesterol, albumin, haemoglobin, and the presence of coronary artery
disease.
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osclerosis and cytokine-induced plaque instability, or by direct
effects on the myocardium, and electrical conduction system.
21
Cytokines are also involved in the modulation of ion channel
function and the generation of arrhythmias,
22,23 as well as in the
aggravation of sympathetic tone, leading to tachycardia and
cardiac electrical instability. In our study, patients with low homo-
arginine concentrations more frequently had arrhythmias, particu-
larly absence of sinus rhythm. Furthermore, we observed a high
burden of CHF and increased levels of brain natriuretic peptide
in patients in the lowest quintile of homoarginine concentration.
These factors are known to be strong predictors of SCD and
may, at least in part, reﬂect the effect of homoarginine on struc-
tural changes in the heart.
17,18,24
The role of homoarginine affecting structural changes in the
heart may also account for its association with heart failure.
Besides the effect on endothelial dysfunction and the release of
cytokines, low homoarginine may also affect blood pressure and
insulin secretion, thus contributing to cardiac hypertrophy, and
ﬁbrosis as major predisposing conditions for heart failure.
Furthermore, it is of high interest that the key enzyme for homo-
arginine synthesis, arginine:glycine amidinotransferase (AGAT), is
upregulated in heart failure.
25 One study found that myocardial
AGAT mRNA expression, and enzyme activity were elevated in
heart failure compared with controls and returned to normal
after functional normalization and recovery. The data indicated
that the expression of AGAT enabled the myocardium to syn-
thesize creatine locally. This upregulation of myocardial AGAT
expression was suggested to be an adaptive process, counteract-
ing the decreased intracellular creatine availability in heart failure
by local creatine production.
25 The notion of AGAT being
involved in cellular energy metabolism is supported by further
data. An experimental study showed that AGAT mRNA was
upregulated in the skeletal muscles of mice with Duchenne mus-
cular dystrophy compared to mature mice.
26 It has been argued
that this process may help maintain muscle creatine levels and
limit cellular energy failure in the leaky skeletal muscles of affected
mice. Extending these data, our study adds important new knowl-
edge by identifying low homoarginine as an important risk factor
for death due to heart failure and also provides a new target for
interventions.
In this context, it is not surprising that the increased risk of
combined cardiovascular events associated with low homoargi-
nine concentrations in our study was mainly explained by the
impact of homoarginine concentration on sudden cardiac and
heart failure deaths. Other studies have suggested that homoargi-
nine plays a role in the pathogenesis of diabetes mellitus and
arterial hypertension.
8,27 Homoarginine has been shown to stimu-
late insulin secretion,
27,28 with glycaemic state meaningfully
increasing the incidence of SCD, but not of myocardial infarc-
tion.
19 The risk of MI as a major macrovascular complication
was not affected by low homoarginine in our study. There was
a moderate effect on stroke, which is thought to result from
both micro- and macrovascular complications. Therefore, the
potential inﬂuence of homoarginine in glucose metabolism and
the importance of microvascular complications may help to
explain the effect on stroke in contrast to myocardial infarction.
Furthermore, previous studies have found that administration of
L-homoarginine increased urinary excretion of nitrate, the degra-
dation product of NO, and reduced blood pressure in salt-
sensitive hypertensive rats.
8 This may explain why we observed
in our study a trend for an association between low homoarginine
concentrations and the incidence of stroke, which is in line with
results from a previous study, identifying low homoarginine as a
novel risk factor for fatal strokes in patients undergoing coronary
angiography.
29 As mentioned above, homoarginine plays a role in
the metabolism of NO, which is—apart from the cardiac
effects—critically involved in the regulation of cerebral blood
ﬂow and cell viability.
30
Figure 1 Kaplan2Meier curves for the time to (A) sudden
cardiac death, (B) myocardial infarction, (C) combined cardiovas-
cular events in subgroups of patients according to the homoargi-
nine concentrations at baseline (quintiles).
Homoarginine and cardiovascular events in dialysis 857Potential limitations of our study need to be acknowledged. It
was a post-hoc analysis within a selected cohort of German
patients with type 2 diabetes mellitus undergoing haemodialysis.
Therefore, the relationship between low homoarginine and
adverse outcomes may not be generalizable to other patient
populations. In this context, potential effects of homoarginine
on MI may not have been seen because of competing risks in dia-
betic dialysis patients. Despite careful adjustments for possible
confounders, we cannot rule out residual confounding.
However, since the known important confounders were con-
sidered, the effect of potential residual confounding is likely to
be small. Furthermore, we cannot draw conclusions regarding
causality from our data but our data indicate that low homoargi-
nine levels reﬂect a novel pathophysiological process related to a
poor cardiovascular outcome. Given that single-nucleotide poly-
morphisms (SNPs) or activity of the key enzyme for homoarginine
synthesis have been previously related to renal and myocardial
diseases supports a causal association between homoarginine
metabolism and adverse health outcomes.The main strengths of
this study are that we were able to analyse speciﬁc outcomes
including SCD. Further strengths include the long-term follow-up,
adequate sample size, and high incidence of pre-speciﬁed and cen-
trally adjudicated endpoints.
In conclusion, low blood homoarginine concentrations were
strongly associated with SCD and death due to heart failure in
haemodialysis patients. Furthermore, there was a trend for low
homoarginine concentrations to be associated with a higher
risk of stroke, but not of myocardial infarction. The risk of
combined cardiovascular events increased signiﬁcantly at lower
concentrations of homoarginine, and was mainly explained by
the impact of homoarginine on sudden cardiac and heart failure
deaths. Longitudinal assessment of homoarginine may be useful
for risk monitoring of dialysis patients. Beyond this, homoarginine
may become a promising novel target for therapeutic inter-
ventions in populations with high incidences of heart failure
and SCD.
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